According to Minister for IT and Industries Duddilla Sridhar Babu, Telangana has set the lofty goal of bringing in Rs. 1 lakh crore in new investments in the life sciences sector by 2030 in order to create jobs for five lakh people
Sai Life Sciences Limited, among India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO), is announcing the ground breaking of a CMC Process R&D Center at its integrated R&D campus in Hyderabad...
India released a list of registered interested parties on Monday, advancing an anti-dumping inquiry into imports of ethambutol hydrochloride, an active pharmaceutical ingredient used in anti-tuberculosis medications, from China and Thailand
GSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic...
Bayosthiti AI, an innovator in AI-driven healthcare and molecular diagnostics, announced a strategic partnership with Narayana Health, one of the world's largest cardiac care networks, to develop AI models that predict cardiovascular disease in India
Health Canada has issued a Notice of Compliance (NOC) to Zydus Lifesciences Limited for their generic 1000 mg mesalamine suppositories
Eli Lilly and Company announced a final deal for Lilly to purchase Adverum Biotechnologies, Inc. (Adverum), including its lead product candidate, Ixo-vec. Adverum Biotechnologies, Inc. is a clinical-stage company that is leading the use of intravitre
In a significant development aimed at bolstering India's medical technology (MedTech) sector, the Anusandhan National Research Foundation (ANRF), in conjunction with the Indian Council of Medical Research (ICMR) and the Gates Foundation...
Eli Lilly and Company revealed today that it is to acquire the clinical-stage biotechnology company Adverum Biotechnologies, Inc., which is the leader in the development of intravitreal gene therapy to restore vision in patients with advanced...
Novartis announced on Sunday that it will acquire U.S.-based Avidity Biosciences for about $12 billion in cash in one of its largest deals to strengthen its pipeline of treatments for rare muscle disorders. Under the terms of the deal, Avidity...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")